This research plan proposes to conduct a double-blind, placebo-controlled pilot clinical
trial in 36 adults with mild Huntington's disease (HD) to address the following research
aims:
1. To determine the effect of citalopram compared to placebo in patients with early HD on
executive function and other outcome variables including functional measures
(health-related quality of life, work productivity, and self-reported attention), motor
performance, and psychiatric status,
2. To study the relationship between executive function and functional status in patients
with early HD after selective serotonin reuptake inhibitor (SSRI) treatment, and
3. To examine the effect of citalopram treatment on volumetric and metabolic (i.e,
N-acetyl-aspartate concentration) measures in the neostriatum among patients with
recently diagnosed Huntington's disease.
Phase:
Phase 2
Details
Lead Sponsor:
University of Iowa
Collaborators:
Cure Huntington's Disease Initiative (CHDI) Mayo Clinic National Institute of Neurological Disorders and Stroke (NINDS) University of Rochester